ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.44667
0.18%
Brent Oil
84.695
-0.11%
Bitcoin
64,795.96
-0.53%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) Noticias

MRUS Merus NV

54.24
-1.53 (-2.74%)
18 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Merus NV MRUS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-1.53 -2.74% 54.24 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
55.76 53.92 55.92 54.24 55.77
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/6/202414:37EDGAR2Form 144 - Report of proposed sale of securities
12/6/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202413:30GLOBEMerus’ MCLA-129 Demonstrates Promising Single-Agent..
02/6/202411:30GLOBEMerus Presents Interim Data on MCLA-145 Monotherapy and in..
30/5/202416:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/5/202420:30GLOBEMerus Announces Pricing of Upsized Public Offering of Common..
29/5/202407:00GLOBEMerus to Participate in a Fireside Chat at the Jefferies..
28/5/202415:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/5/202415:06EDGAR2Form 8-K - Current report
28/5/202415:01GLOBEMerus N.V. Announces Proposed Public Offering of Common..
28/5/202406:00GLOBEMerus’ Petosemtamab in Combination with Pembrolizumab..
23/5/202416:00GLOBEMerus Announces Publication of an Abstract on Petosemtamab..
13/5/202407:00GLOBEPetosemtamab granted Breakthrough Therapy Designation by the..
10/5/202415:33EDGAR2Form 8-K/A - Current report: [Amend]
09/5/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202415:15GLOBEMerus Announces Financial Results for the First Quarter 2024..
08/5/202407:01EDGAR2Form 8-K - Current report
06/5/202415:05GLOBEMerus Announces U.S. FDA Acceptance and Priority Review of..
08/4/202411:00GLOBEMerus Presents Preclinical Data Demonstrating Efficacy of..
03/4/202407:00GLOBEMerus to Participate in a Fireside Chat at the 23rd Annual..
06/3/202407:15EDGAR2Form 8-K - Current report
06/3/202407:00BWGilead and Merus Announce Collaboration to Discover Novel..
05/3/202415:30GLOBEMerus Announces Publication of an Abstract for Presentation..
04/3/202407:00GLOBEMerus to Participate in a Fireside Chat at the Leerink..
28/2/202415:55EDGAR2Form S-3ASR - Automatic shelf registration statement of..
28/2/202415:15GLOBEMerus Announces Financial Results for the Fourth Quarter and..
14/2/202415:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202407:00GLOBEMerus to Participate in Upcoming Investor Conferences
20/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202316:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202318:29EDGAR2Form 144 - Report of proposed sale of securities
12/12/202315:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202319:40GLOBEMerus Presents Interim Data on MCLA-129 at ESMO Asia..
01/12/202309:47EDGAR2Form 144 - Report of proposed sale of securities
26/11/202310:05GLOBEMerus Announces Publication of Abstracts on MCLA-129 for..
02/11/202315:12GLOBEMerus Announces Financial Results for the Third Quarter 2023..
02/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202307:00GLOBEMerus to Participate in Upcoming Investor Conferences
23/10/202306:30GLOBEMerus’ Zeno Interim Data Continues to Demonstrate Robust and..
15/10/202318:58GLOBEMerus Announces Business Update Conference Call
11/10/202315:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
MRUS
Merus NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados